Olux Related Published Studies
Well-designed clinical trials related to Olux (Clobetasol Topical)
Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in
children: a randomized clinical trial. [2014]
A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05%
clobetasol propionate ointment in discoid lupus erythematosus by modified
cutaneous lupus erythematosus disease area and severity index. [2012]
A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo. [2011.09]
Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. [2011.08]
Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. [2011.08]
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. [2011.07]
A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. [2011.06]
A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1%
vs. clobetasol propionate 0·05% in childhood vitiligo. [2011]
A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in
patients with vulvar lichen sclerosus. [2011]
Excimer laser vs. clobetasol propionate 0.05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. [2010.10]
Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. [2010.05]
Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. [2010.01]
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. [2010.01]
Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations. [2010]
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. [2009.08.03]
Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis. [2009.03]
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.03]
Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. [2009.02]
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.01.08]
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. [2009.01]
Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. [2008.12.26]
Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. [2008.09]
The efficacy of '0.05% Clobetasol + 2.5% zinc sulphate' cream vs. '0.05% Clobetasol alone' cream in the treatment of the chronic hand eczema: a double-blind study. [2008.05]
Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. [2008.03]
A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. [2008.02]
Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. [2007.05]
Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. [2007.01]
Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. [2007]
Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. [2006.11]
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. [2006.10]
An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. [2006.04]
Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. [2006.04]
Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial. [2006.02]
Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial. [2006.01]
A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. [2006]
Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. [2005.08]
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. [2005.05]
Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. [2005.02]
Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. [2004.09]
Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. [2004.07]
A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial. [2004.05]
Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. [2003.11]
Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis. [2003.07]
The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. [2003.07]
A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. [2003.05]
The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. [2003.05]
Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. [2003.05]
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. [2002.05]
Flow cytometric assessment of clearance and relapse characteristics in psoriasis vulgaris after treatment with weekly clobetasol lotion under hydrocolloid occlusion versus twice-daily clobetasol ointment. [2002.03]
The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. [2001.11]
Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. [2001.09]
The therapeutic efficacy of mometasone furoate cream 0.1% applied once daily vs clobetasol propionate cream 0.05% applied twice daily in chronic eczema. [1999.05]
Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. [1999.01]
Efficacy of topical mesalazine compared with clobetasol propionate in treatment of symptomatic oral lichen planus. [1998.12]
Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. [1998.07]
Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. [1998.02]
Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis. [1997.07]
Topical clobetasol propionate compared with placebo in the treatment of unretractable foreskin. [1996.12]
Testosterone maintenance therapy. Effects on vulvar lichen sclerosus treated with clobetasol propionate. [1996.02]
0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects. [1996]
The effects of topical indomethacin and clobetasol propionate on post-cryotherapy inflammation. [1995.05]
Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. [1995.05]
Double-blind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. [1994.06]
Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. [1994]
A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. [1991.12]
A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. [1991.12]
Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. [1991.12]
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. [1991.03]
A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis. [1990.11]
Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide. [1989.12]
Well-designed clinical trials possibly related to Olux (Clobetasol Topical)
[Bullous pemphigoid: a review]. [2011.03]
Applicability of an exaggerated forearm wash test for efficacy testing of two corticosteroids, tacrolimus and glycerol, in topical formulations against skin irritation induced by two different irritants. [2011.02]
Dermasilk briefs in vulvar lichen sclerosus: an adjuvant tool. [2011]
The treatment of vulvar lichen sclerosus and female sexual dysfunction. [2011]
A new mucoadhesive dosage form for the management of oral lichen planus: formulation study and clinical study. [2010.11]
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. [2009.07]
A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study. [2009.01.29]
Topical corticosteroids in the treatment of acute sunburn: a randomized, double-blind clinical trial. [2008.05]
Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. [2007.07]
Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. [2007.07]
Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial. [2007.06]
Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers. [2007]
Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial. [2006.10]
Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. [2006.08]
Prediction of survival for patients with bullous pemphigoid: a prospective study. [2005.06]
Highly potent and moderately potent topical steroids are effective in treating phimosis: a prospective randomized study. [2005.04]
Fluocinolone acetonide topical oil for scalp psoriasis. [2004.12]
Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. [2004.10]
Treatment of bullous pemphigoid. [2003.02]
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. [2003]
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. [2002.01.31]
VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis. [2000.02]
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. [1998.12]
Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. [1998.10]
Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. [1998.09]
Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. [1998.08]
Inhibition of elicitation of contact dermatitis in humans by mometasone furoate: evaluation by means of 20-MHz B scanning associated with image analysis. [1997]
Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study. [1996.09]
Validation of an in vivo wound healing model for the quantification of pharmacological effects on epidermal regeneration. [1995]
The effects of topical corticosteroids on delayed pressure urticaria. [1995]
Topical glucocorticoid has no antinociceptive or anti-inflammatory effect in thermal injury. [1994.04]
|
